Los agonistas del receptor GLP-1 (GLP-1 RAs) como liraglutida, semaglutida o exenatida son medicamentos desarrollados para imitar la accin del GLP-1 que producimos, pero con estructuras qumicas modificadas para mejorar su vida media y eficacia
These are all part of a class of drugs called GLP-1 agonists, and they're making waves in how we manage conditions like type 2 diabetes and obesity
The following parameters were tested: total motility (TM, %), progressive motility (PM, %), linearity (LIN, %), average path velocity (VAP, m/s), straight line velocity (VSL, m/s), curvilinear velocity (VCL, m/s), beat cross frequency (BCF, Hz)
For the first time in modern medical history, we FINALLY have the pharmacological means to effectively and safely treat obesity (and the many conditions that result from it) by target multiple biological pathways at once
A., Harsoyo, P